Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

• Prif Awduron: Khalid Alhazzani (Awdur), Meshal Alsahli (Awdur), Ahmed Z Alanazi (Awdur), Mohammad Algahtani (Awdur), Ahmad A Alenezi (Awdur), Ali Alhoshani (Awdur), Mohammed Alqinyah (Awdur), Abdullah S. Alhamed (Awdur), Khaled Alhosaini (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Elsevier, 2023-10-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...